Johnson & Johnson COVID-19 vaccine deemed 'safe and effective' by the FDA

Automatic TRANSCRIPT

And johnson. It's been shown that they're vaccine is effective at preventing hospitalizations and severe effects of covid. Nineteen this from scientists at the fda we're seeing about. I think it's sixty six percent effective when it comes to moderate to severe cases of covid nineteen so matthew. Tell a little bit more about what we're hearing with. His johnson and johnson vaccine right so what happened. Is that johnson. Johnson released data about a month ago. You know press release but the process for evaluating these vaccines is that they go through the fda and the fda really unique in the world independently looks at the data and re analyzes the data that the company produces and its own report and then hold a public meeting which will be happening friday and so the documents before the public meeting came out and they had some good news both some really clear data on hospitalizations and a general sense of approval from the fda researchers. Sometimes they're not as positive so it looks like this may be another option now. The big plus is on. This is one. It's a one shot dose. So you don't have to go back for a second jab in the arm and also doesn't need to be kept frozen like the pfizer derna vaccines do so shipping and handling of all of this will be a lot easier much easier to transport and that's a big advantage. It does not look like we're gonna have a huge amount of supply the start off with so it doesn't dramatically change how fast we're going to be any shots into people's arms but for a lot of people i think in a lot of experts i talked. You think this'll be a great option. It's one and done. I think some of the numbers. I saw the might have about four. That are produced right now. Ready to send out so it gets approved. They can get those out really quick but it wouldn't be until april possibly where they can really ramp up production to start distributing that right and will also be getting over that where they're hundreds of millions of doses of the two vaccines have the madonna and fayza biontech vaccines. That are expected to arrive in the us by july. So there's gonna be a lot more vaccine available. The jj supply will ramp up and we'll be getting more of those other two vaccines that leaves. There's a vaccine coming from nova vacs. We don't really know about how much will getting the early results issued press. Release again good and we're waiting for. Us results on the astra zeneca vaccine. Now some good news. With his johnson and johnson one is its effectiveness against these variants. That we've been hearing a lot about so it fared better than expected when it comes to those. I the way to interpret. That is we'd seen some results and the new results that they showed today look a bit better than what we'd seen in terms of variants. There's still does seem to be decreased. Efficacy against the south africa variant. Three five. Which is really the one that we're all worried about but it did look better than what we've seen previously and what j. j. has said it seems like with those variants. This vaccine is still preventing severe disease and hospitalization. Which are the key things. We've always wanted from vaccine here. The idea that you'd prevent a symptomatic infection or mild cases kind of bonus compared to just making sure that people end up in the hospital hospitalizations numbers were good on that front. What did we see when it comes to side effects. I saw that there were a few unexpected side effects. Although these are very rare you know but The expecting side effects the kind of pain in the arm the headache fatigue. That's pretty much in line with the other two vaccines. We have that right now. There were some rare events that occurred more often in the vaccine in the placebo group. Keeping in mind that forty thousand people were in this trial. There were fifteen serious blood clots including some. Dvd's in that exciting compared to ten in the placebo group. That's something the fda plans to monitor there was also some rini ears in the vaccine group and not in the placebo group. So that's kind of an odd one that will wanna watch again. This is really a prelude to friday win. Some of the top experts in the world are going to gather on zoom call and go over these data that the fda assembled we'll be live blogging that stat. That's when we really find out a lot about any medical product. It's it's one of the amazing things. The fda does now an interesting thing in all of this so public health officials might have a messaging problem when it comes to pumping the johnson and johnson. One out when we're seeing guys like pfizer maderna's say that their vaccine is ninety five percent effective against corona virus. Just listening to numbers right. This says sixty six percent. So what are they going to have a challenge in getting people to want to take this one over the other or you know how how to work out. It's really important to realize that particularly between those three vaccines. The getting vaccine is much better than not getting a vaccine. The change vaccine may be on par after a second dose and that study is being done but unlike visor during the second dose is going to be months after the first and then also slows down the study. She gotta wait right for people to get their second dose. So we're not expecting those data until kinda summerish but the big thing is for a lot of people. There was also the appeal of a single dose here. And i don't think we should understate that. And the effect on severe disease is big so the problem is gonna be the in the initial rollout. You really want people to take whatever vaccine. They're giving because being vaccinated is so much better than not being vaccinated. And that is part of the path to get in the world back to normal and public health. Authorities are absolutely going to have to articulate that now again because there's not going to be that much supply of this initially. They're going to have time for a learning curve right now. the demand for vaccines clearly outstrips supply. That's why you're hearing so many stories of people desperately logging on trying to get vaccine. What scott gottlieb used to run. The fda has raised the issue of you know. We're we're going to reach a point where the people who wanna get vaccinated we'll have been vaccinated and we're still going to need to vaccinate more people and that's when convincing people who are less sure to take vaccine in to take the vaccine that's available is going to become more of an issue last question briefly pfizer moderna vaccines are based on 'em a. What kind of platform is the johnson and johnson. When using this like theatrics annika vaccine is called an ad no virus which is a kind of virus that is used to the same kind of ideas marin a the instead of traditional vaccines were you inject the protein that your immune system sees and then learn to recognize an attack. These sneak something into your body that makes a lot of proteins. You make a lot more protein and then the body recognizes that an attack it in this case they're using this virus which is kind of a cold virus to sneak some genetic material in and that makes the spike protein from the sars virus which your body then learns to recognize and thereby has antibodies that attack the virus

Coming up next